May 21, 2007
Molecular Biometrics LLC, a privately held metabolomics company, has conducted a pilot study to identify diagnostic biomarkers for idiopathic Parkinson’s disease.
This study was based on Molecular Biometrics’ proprietary biospectroscopy-based metabolomics (BSM) platform. Investigators utilized the company’s BSM platform to assess biomarkers of oxidative metabolism (OM) in the plasma of Parkinson’s patients.
The study found that both Raman spectroscopy and near infrared spectroscopy, also known as vibrational spectroscopy or VS, could be used to reproducibly identify and quantify biomarkers of OM with a sensitivity and specificity of greater than 75%.
The biomarkers produced characteristic metabolomic profiles, or fingerprints that could distinguish patients with Parkinson’s from normal elderly controls and from patients with other neurological disorders such as Alzheimer’s disease.
For more information visit the company’s Web site.
